School of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
Department of Pharmacy, Tianjin Medical University General Hospital, Tianjin, 300070, China.
Oncol Res. 2024 Sep 18;32(10):1661-1671. doi: 10.32604/or.2024.048287. eCollection 2024.
Glutamine is one of the most abundant non-essential amino acids in human plasma and plays a crucial role in many biological processes of the human body. Tumor cells take up a large amount of glutamine to meet their rapid proliferation requirements, which is supported by the upregulation of glutamine transporters. Targeted inhibition of glutamine transporters effectively inhibits cell growth and proliferation in tumors. Among all cancers, digestive system malignant tumors (DSMTs) have the highest incidence and mortality rates, and the current therapeutic strategies for DSMTs are mainly surgical resection and chemotherapy. Due to the relatively low survival rate and severe side effects associated with DSMTs treatment, new treatment strategies are urgently required. This article summarizes the glutamine transporters involved in DSMTs and describes their role in DSMTs. Additionally, glutamine transporter-target drugs are discussed, providing theoretical guidance for the further development of drugs DSMTs treatment.
谷氨酰胺是人体血浆中含量最丰富的非必需氨基酸之一，在人体的许多生物学过程中发挥着关键作用。肿瘤细胞摄取大量的谷氨酰胺来满足其快速增殖的需求，这是由谷氨酰胺转运体的上调所支持的。靶向抑制谷氨酰胺转运体可有效抑制肿瘤细胞的生长和增殖。在所有癌症中，消化系统恶性肿瘤（DSMTs）的发病率和死亡率最高，目前 DSMTs 的治疗策略主要是手术切除和化疗。由于 DSMTs 治疗的生存率相对较低和严重的副作用，迫切需要新的治疗策略。本文总结了参与 DSMTs 的谷氨酰胺转运体，并描述了它们在 DSMTs 中的作用。此外，还讨论了谷氨酰胺转运体靶向药物，为进一步开发 DSMTs 治疗药物提供了理论指导。
